Fudan anticancer drug patent license to American companies

06:55 March 17, 2016

Source: Chinese

On March 15, fudan university and the United States HUYA (Shanghai) company in Shanghai to reach an agreement, the school will have independent intellectual property rights licensed to American IDO inhibitors for cancer immunotherapy HUYA company. According to the agreement, the company will adopt the way of phased payment pay to fudan university has no more than $65 million (RMB 424 million).

> > agreement

Complete stage goals, to $65 million

Yesterday, fudan university press office staff confirmed to the Chinese press, the school really HUYA company signed with the United States immune oncology cooperation agreement. The IDO inhibitors is by fudan university college of life science of genetics and developmental biology, genetic engineering, state key laboratory of collaborative innovation center, professor Yang qing group after more than 10 years of research and development of enzyme indoleamine 2, 3 - two-plus oxygen (IDO) new inhibitors. As a tumor immunotherapy targeting drug, IDO inhibitors is a good potential anti-cancer, the collaboration will combine the HUYA rich clinical experience, to accelerate the process of development of inhibitor of IDO, clinical application as soon as possible. However, project director Yang qing said the current inconvenience for an interview.

According to the agreement, the company will receive the drug in addition to mainland China, Hong Kong, Macao and Taiwan regions outside of the global clinical development and market sales of exclusive rights. HUYA company will cooperate with professor Yang qing group to carry out clinical trials, to promote the project development and marketing work.

Surge, according to news reports, HUYA company will pay a certain amount of down payment to fudan university. If the IDO inhibitors abroad clinical trial results achieved superior effect; Successfully listed in the European Union, the United States, Japan; And annual sales reach different goals, HUYA companies in the United States pay to fudan university has no more than $65 million each milestone payment (set goals in stages a payment).

> > experts read

Is not sell patent, license only each other in the overseas development sales

The news triggered heated debate after media reports, some netizens question: why not to sell to the domestic company? So the hard work out of patent sold to foreign countries, then somebody else take drugs to sell back to China?

Yesterday, the China university of political science and law of intellectual property research center, associate professor, civil and commercial economic law professor liu know letter of Chinese reporters interview, said the patent license and patent transfer has essential difference, fudan university, still have the ownership of the patent, the HUYA company signed with the United States have limited regional exclusive license agreement, in mainland China and Hong Kong, Macao and Taiwan regions, HUYA companies in the United States has the exclusive license the patents, fudan university shall not give the patent license to a third party, may not be used by themselves. But still, in mainland China and Hong Kong, Macao and Taiwan, fudan university has the right to the patent license and transfer to any third party; If the license agreement, without the agreement which has also the patent can be transferred to a third party overseas. "As long as not involving national security and secrets, licensing and technology transfer are very normal technology trade, no legal obstacles, not restricted."

Liu letter said, the price of $65 million is not a "day price", for the new drug research and development, and even can be said to be relatively cheap. The news can cause sensation, because our country independent research and development of new drugs is relatively backward, domestic output to foreign patent case of too little.

"Is a new drug research and development investment, high risk, periodic long process, research and development of most of the time to finally faced failure, domestic drug firms have invested a lot of money and manpower to strength a handful of new drug research and development". Liu know letter pointed out that, on the one hand, the domestic medicine companies to independent research and development of new drugs' enthusiasm is not high, often the pursuit of the interests of the rapid spike, so that most is given priority to with generic drugs, generic drug patents expire abroad in particular. On the other hand, China's new drug approval is stricter, administrative examination and approval procedure is tedious, also the enthusiasm of research and development of new drugs have an effect to drug companies.

> > success

Previous research has over 10 years

It is understood that IDO is a cell contains the enzyme of heme, widely distributed in many tissues and cells of humans and animals. At present, IDO has proved to be an important drug discovery targets, IDO inhibitors as new drugs, new drug targets, can be applied to treat cancer, alzheimer's disease, depression, cataracts, and other major diseases.

He team since 2006 IDO inhibitor research and development work and made a good foundation. At present, foreign pharmaceutical industry for market prospects on IDO inhibitor drugs, many foreign well-known drug firms have announced to join IDO inhibitors of r&d competition. But IDO inhibitors widely existing inhibition effect is low, there is no IDO inhibitor drugs. So far, the United States Newlink Genetics company Incyte company research and development of related compounds with the United States has entered clinical trials. And he take the lead in research and development of new type IDO inhibitor, has been applied for and include all IDO inhibitors in China with Chinese intellectual property invention patent, and the related international has applied for patents, is expected to become the third IDO inhibitors in clinical trials research.

He graduated in 2000 from the Japanese island of Hokkaido university bioorganic chemistry, a doctor's degree. Then successively in Japan Hokkaido university, gifu university, university of Tokyo for postdoctoral research. President of fudan university in 2006, to return home, associate professor of college of pharmacy, college of life science, 2011, doctoral supervisor, professor in 2012. Chinese journalists Liu Miao

> > link

Antitumor IDO inhibitors against alzheimer's disease has a huge market potential

According to the WHO statistics, each year over the past few years the world up to more than 7 million people died of cancer patients. In this case, the antitumor drug market is growing rapidly. Prediction, head of the international monetary fund: global cancer drugs market annual growth rate of 15%, far more than the growth rate of other drugs.

Alzheimer's disease, on the other hand, has become a fourth largest cause of endangering the elderly life, as the world's greying, after 20 years of alzheimer's disease will be from 35 million today to 65.7 million people. Global fight alzheimer's drug market scale has hit $2009 in 5.5 billion, and in the future will also be growing at an alarming rate.

Under the above background, the study of IDO and major diseases such as cancer, alzheimer's disease to reveal the relationship between the pathogenesis of these diseases have important value, IDO inhibitors as a molecular target drug has a huge market potential. Cases of combined